(1.13%) 5 105.34 points
(0.51%) 38 282 points
(2.03%) 15 929 points
(0.22%) $83.75
(-1.16%) $1.619
(0.38%) $2 351.30
(-0.08%) $27.33
(0.29%) $923.15
(0.27%) $0.934
(0.62%) $11.02
(0.08%) $0.800
(-0.34%) $91.86
Live Chart Being Loaded With Signals
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders...
Stats | |
---|---|
Today's Volume | 679 546 |
Average Volume | 506 520 |
Market Cap | 1.91B |
EPS | £0 ( 2024-04-24 ) |
Next earnings date | ( £0 ) 2024-07-25 |
Last Dividend | £36.50 ( 2016-06-16 ) |
Next Dividend | £0 ( N/A ) |
P/E | 1 408.00 |
ATR14 | £2.32 (0.16%) |
Volume Correlation
Indivior PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Indivior PLC Correlation - Currency/Commodity
Indivior PLC Financials
Annual | 2023 |
Revenue: | £1.09B |
Gross Profit: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2023 |
Revenue: | £1.09B |
Gross Profit: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2022 |
Revenue: | £901.00M |
Gross Profit: | £742.00M (82.35 %) |
EPS: | £-0.380 |
FY | 2021 |
Revenue: | £791.00M |
Gross Profit: | £664.00M (83.94 %) |
EPS: | £1.410 |
Financial Reports:
No articles found.
Indivior PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £10.40 | 2015-09-17 |
Last Dividend | £36.50 | 2016-06-16 |
Next Dividend | £0 | N/A |
Payout Date | 2016-07-29 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £46.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.12 | -- |
Div. Sustainability Score | 4.95 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.992 | -- |
Year | Amount | Yield |
---|---|---|
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £0 | 0.00% |
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SPI.L | Dividend Junior | 2023-05-25 | Annually | 10 | 0.18% | |
JHD.L | Dividend King | 2023-05-11 | Semi-Annually | 32 | 1.47% | |
CAML.L | Dividend Knight | 2023-09-28 | Annually | 12 | 3.83% | |
PMP.L | Dividend Junior | 2023-11-16 | Annually | 32 | 1.59% | |
GBG.L | Dividend Junior | 2023-06-22 | Annually | 22 | 0.51% | |
AJB.L | Dividend Knight | 2023-06-08 | Semi-Annually | 6 | 1.30% | |
TFIF.L | Dividend Knight | 2023-07-20 | Quarterly | 12 | 4.62% | |
LRE.L | Dividend Knight | 2023-08-17 | Semi-Annually | 16 | 1.26% | |
COA.L | Dividend Knight | 2023-10-19 | Annually | 33 | 1.79% | |
RHIM.L | Dividend Knight | 2023-08-24 | Annually | 7 | 3.49% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00183 | 1.500 | 9.96 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00102 | 1.200 | 9.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00542 | 1.500 | -1.051 | -1.576 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.968 | 0.800 | -0.161 | -0.129 | [1 - 3] |
quickRatioTTM | 0.526 | 0.800 | -1.609 | -1.287 | [0.8 - 2.5] |
cashRatioTTM | 0.242 | 1.500 | 9.77 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.144 | -1.500 | 7.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0.553 | 1.000 | -0.906 | -0.906 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -1.339 | -2.68 | [0 - 20] |
debtEquityRatioTTM | 0.215 | -1.500 | 9.14 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.830 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.616 | -1.616 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.117 | 1.000 | -7.32 | -7.32 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.60 | 7.68 | [0.5 - 2] |
Total Score | 4.95 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1 202.59 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00542 | 2.50 | -0.676 | -1.576 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -0.892 | -2.68 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.288 | 1.000 | -9.70 | 0 | [0.1 - 0.5] |
Total Score | -0.971 |
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators